Aurobindo Pharma Limited (BSE:524804) made an offer to acquire generics commercial operations in seven markets from Actavis plc (NYSE:ACT) for €30 million on January 17, 2014. The transaction is subject to antitrust approvals and completion of employee consultation processes, which is anticipated in the year ending December 31, 2014. Stefano Beschi and Julian Hudson of Rothschild acted as financial advisors and R. Scott Shean of Latham & Watkins and Mário Lino Dias, Miguel Menezes da Silva and Francisca Sousa Guedes of Garrigues Portugal, S.L.P. – Sucursal acted as legal advisors to Actavis.

Jefferies International Limited acted as financial advisor and Alan Montgomery, Robert Moore, Brian O'Malley, Francis Dalton and Imran Bhatia of Herbert Smith Freehills LLP and Campos Ferreira, Sá Carneiro & Associados acted as legal advisors to Aurobindo.